Bristol-Myers Squibb (BMY)
$66.38 0.30 (0.45%)
19:18 EST BMY Stock Quote Delayed 15 Minutes
Previous Close $66.38
Market Cap 108.50B
PE Ratio 116.46
Volume (Avg. Vol.) 7.53M
Day's Range 65.98 - 66.83
52-Week Range 42.48 - 68.34
Dividend & Yield 1.60 (2.41%)
BMY Stock Predictions, Articles, and Bristol-Myers Squibb News
- From InvestorPlace
- From the Web
Amgen's purchase of Celgenes blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space and boost Amgen stock.
Trade talks gave a lift to stocks, while Johnson & Johnson will be in focus after the close. Here's what happened in the stock market today.
Netflix, Amgen, Bristol-Myers Squibb, Aurora Cannabis and Foot Locker are our top stock trades for Tuesday. Here's how to trade them.
Celgene news for Thursday about it selling Otezla has CELG stock on the rise as it moves forward with the Bristol-Myers Squibb merger.
Healthcare stocks are among the best growth and income plays. Here are five firms in the sector that have the goods to keep growing and paying strong dividends.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Bristol-Myers Squibb stock touched a multi-year low last month. But the BMY stock price is cheap enough now to take on real risks.
Political pressures regarding drug pricing and Bristol-Myers’ disappointing clinical trails have contributed to a disappointing performance for BMY stock. Still, much of this bearishness could be priced in already.
BMY stock may continue to bounce around, but the months-long selloff is now slowing because Bristol-Myers Squibb is still thriving.
Stock were hit on Thursday as investors try to parse through a deluge of earnings results. Here's what moved the stock market today.
Bristol-Myers Squibb earnings for the second quarter of the year have BMY stock on the move Thursday after it beat estimates.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Drug stocks are falling on fears of President Trump's next move on drug prices. Here's a look at the charts.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
AbbVie is buying Allergan, FedEx and Blackberry are reporting earnings and Microsoft is on the move. Here are our top stock trades.
The stock charts of EA, AAP and MGM have run through the technical trading wringer in front of today's action.
Celgene and Bristol-Myers Squibb stocks took a hit, video games rallied and Caesars Entertainment entered into a $17.3 billion merger. Here's the Nasdaq Today report.
From Talk Markets
Analysts Offer Insights on Healthcare Companies: Bristol Myers (NYSE: BMY) and Exelixis (NASDAQ: EXEL)
From Analyst Ratings
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol Myers (BMY – Research Report) and Exelixis (EXEL – Research Report) with bullish sentiments. Bristol Myers (BMY) William Blair analyst Matt Phipps maintained a Buy rating on Bristol Myers yesterday. The company’s shares closed last Monday
Navellier RatingsPowered by Portfolio Grader